Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Carl Icahn May Not Get His Way At Biogen Idec

This article was originally published in The Pink Sheet Daily

Executive Summary

Activist’s new plan could imply short-term gain and swift exit, may not sway shareholders in June vote, analysts say.

You may also be interested in...



Amylin Chair And Lead Independent Director Voted Off The Board

The ouster underscores the extent to which dissident shareholders, led by Carl Icahn, have had influence as Amylin hopes to win approval of a key diabetes drug.

Amylin Chair And Lead Independent Director Voted Off The Board

The ouster underscores the extent to which dissident shareholders, led by Carl Icahn, have had influence as Amylin hopes to win approval of a key diabetes drug.

Icahn And Eastbourne Win Some, Lose Some In Amylin Match

Dissident shareholders Carl Icahn and Eastbourne Capital Management have managed to snare two seats on Amylin's 12-person board of directors, enough to hold the firm's feet to the fire but not enough to command a major change of course

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel